DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20170957

Protective effect of tadalafil in diabetic nephropathy induced rat model

Abdel Hamid M. Elhawary, Omaima M. Abd Allah

Abstract


Background: Among various mechanisms involved in the pathogenesis of diabetic nephropathy (DN), abnormalities in renal nitric oxide (NO) generation has attracted a lot of attention. Tadalafil, a competitive inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 commonly used in the treatment of erectile dysfunction was suggested to play a potential prophylactic role for DN. However, this role has not been fully elucidated. The present study was designed to explore the potential beneficial effect of low- dose tadalafil on the progression of diabetic nephropathy in streptozotocin (STZ) induced diabetic rat model.

Methods: After injection of STZ and verifying establishment of diabetes, rats were divided into 4 groups: control, diabetic-control, tadalafil-treated non-diabetic, and tadalafil-treated diabetic groups. Biochemical and hemodynamic parameters affecting the renal function such as blood glucose level, serum level of urea and creatinine, renal blood flow, urine volume, urinary albumin excretion, Na+ and K+ excretion, renal level of nitrite and nitrate, plus renal tissues antioxidant parameters (total antioxidant capacity, superoxide dismutase activity and glutathione content) were detected 8 weeks after administration of tadalafil. Histopathological and electron microscopy examination were performed.

Results: Our results demonstrated that tadalafil attenuated the glycemic, renal biochemical, microscopic and ultramicroscopic changes/injuries caused by STZ- induced diabetes. Tadalafil could effectively increase renal blood flow and ameliorate glomerular basement membrane thickening.

Conclusions: From the results it can be concluded that tadalafil protects rats against streptozotocin-induced DN possibly, in part, through its effect on renal nitric oxide level and its antioxidant activity.


Keywords


Diabetic nephropathy, Histopathological changes, Oxidative stress, Rats, Tadalafil

Full Text:

PDF

References


Arora MK, Singh UK. Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update. Vascul Pharmacol. 2013;58(4):259-71.

Dellamea BS, Leitão CB, Friedman R, Canani LH. Nitric oxide system and diabetic nephropathy. Diabetol Metab Syndr. 2014;12,6(1):17.

Forbes JM, Fukami K, Cooper ME. Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes. 2007;115:69-84.

Giunti S, Barit D, Cooper ME. Mechanisms of diabetic nephropathy: role of hypertension. Hypertension. 2006;48:519-26.

Yan C, Kim D, Aizawa T, Berk BC. Functional interplay between angiotensin II and nitric oxide: cyclic GMP as a key mediator. Arterioscler Thromb Vasc Biol. 2003;23:26-36.

Daugan A, Grondin P, Ruault C, Le Monnier de Gouville AC, Coste H, et al. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor: 1:5,6,11,11a-tetrahydro-1H-imidazo[1’,5’:1,6]pyrido [3,4-b]indole-1,3(2H)-dione analogues. J Med Chem. 2003;46:4525-32.

Wright PJ. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract. 2006;60(8):967-75.

Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil-review of the literature. Eur J Med Res. 2002;7(10):435-46.

Varma A, Das A, Hoke NN, Durrant DE, Salloum FN, Kukreja RC. Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice. PLoS One. 2012;7(9):e45243.

Koka S, Das A, Salloum FN, Kukreja RC. Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice. Free Radic Biol Med. 2013;60:80-8.

Paget GE, Barnes JM. Toxicity tests in evaluation of drug activities pharmacometries (Laurence, DR and Bacharach AL eds) Academic Press, London and New York, 1964.

Patterson E, Marques TM, O’Sullivan O, Fitzgerald P, Fitzgerald GF, Cotter PD et al. Streptozotocin-induced type-1-diabetes disease onset in Sprague–Dawley rats is associated with an altered intestinal microbiota composition and decreased diversity. Microbiol. 2015;161:182-93.

Tinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol. 1969;22(2):158-61.

Sastry KV, Moudgal RP, Mohan J, Tyagi JS, Rao GS. Spectrophotometric determination of serum nitrite and nitrate by copper-cadmium alloy. Anal Biochem. 2002;1,306(1):79-82.

Sesti C, Florio V, Johnson EG, Kloner RA. The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size. Int J Impot Res. 2007;19(1):55-61.

Sawamura F, Kato M, Fujita K, Nakazawa T, Beardsworth A. Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats. J Pharmacol Sci. 2009;111(3):235-43.

Lux A, Pokreisz P, Swinnen M, Caluwe E, Gillijns H, Szelid Z, et al. Concomitant phosphodiesterase 5 inhibition enhances myocardial protection by inhaled nitric oxide in ischemia-reperfusion injury. J Pharmacol Exp Ther. 2016;356(2):284-92.

Wang L, Chopp M, Szalad A, Lu X, Jia L, Lu M, et al. Tadalafil promotes the recovery of peripheral neuropathy in type ii diabetic mice. Plos One. 2016;11(7):e0159665.

Bell TD, DiBona GF, Wang Y, Brands MW. Mechanisms for renal blood flow control early in diabetes as revealed by chronic flow measurement and transfer function analysis. J Am Soc Nephrol. 2006;17(8):2184-92.

Arima S, Ito S. The mechanisms underlying altered vascular resistance of glomerular afferent and efferent arterioles in diabetic nephropathy. Nephrol Dial Transplant. 2003;18:1966-9.

Morcos SK. Can selective inhibitors of cyclic guanosine monophosphate (cGMP)-specific phosphadiesterase type 5 (PDE 5) offer protection against contrast induced nephropathy? Quant Imaging Med Surg. 2014;4(4):214-5.

De Nicola L, Gabbai FB, Liberti ME, Sagliocca A, Conte G, Minutolo R. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. Am J Kidney Dis. 2014;64(1):16-24.

Gasanov F, Aytac B, Vuruskan H. The effects of tadalafil on renal ischemia reperfusion injury: an experimental study. Bosnian J Basic Med Sci. 2011;11(3):158-162.

Ozbek K, Ceyhan K, Koc F, Sogut E, Altunkas F, Karayakali M, et al. The protective effect of single dose tadalafil in contrast-induced nephropathy: an experimental study. Anatol J Cardiol. 2015;15(4):306-10.

Arora MK, Singh UK. Oxidative stress: meeting multiple targets in pathogenesis of diabetic nephropathy. Curr Drug Targets. 2014;15(5):531-8.

Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circu Res. 2010;107:1058-70.

Ding H, Aljofan M, Triggle CR. Oxidative stress and increased eNOS and NADPH oxidase expression in mouse microvessel endothelial cells. J Cell Physiol. 2007;212:682-9.

Serarslan Y, Yonden Z, Ozgiray E, Oktar S, Guven EO, Sogut S, et al. Protective effects of tadalafil on experimental spinal cord injury in rats, J. Clin. Neurosci. 2010;17:349-52.

Chen Y, Li XX, Lin HC, Qiu XF, Gao J, Dai YT, et al. The effects of long-term administration of tadalafil on STZ-induced diabetic rats with erectile dysfunction via a local antioxidative mechanism, Asian J. Androl. 2012;14:616-20.

Koka S, Xi L, Kukreja RC. Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type II diabetic hearts. Basic Res Cardiol. 2012;107:249.

Sheweita S, Salamaa B, Hassanb M. Erectile dysfunction drugs and oxidative stress in the liver of male rats. Toxicology Reports. 2015;2:933-8.